logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10188602 B1

PDFFull Text
Date of Patent:
Jan. 29, 2019

Filed:

Sep. 29, 2017

Bioerodible implant for long-term drug delivery and associated methods of manufacture and use

Applicant:

Gesea Biosciences Inc., Lynnwood, WA (US);

Inventors:

John H. Baillie, Glen Ellen, CA (US);

Ruth Baillie, Glen Ellen, CA (US);

George Blouin, Lynnwood, WA (US);

Newsha Farahani, Issaquah, WA (US);

Christopher Marx, Mukilteo, WA (US);

Assignee:

GESEA BIOSCIENCES INC., San Luis Obispo, CA (US);

Attorneys:

Dianne E. Reed

VLP Law Group LLP

Primary Examiner:

Bethany P Barham

Assistant Examiner:

Dominic Lazaro

Int. Cl.
CPC ...
A61F 6/08 (2006.01); A61F 6/22 (2006.01); A61K 9/00 (2006.01); A61K 31/167 (2006.01); A61K 31/192 (2006.01); A61K 31/325 (2006.01); A61K 31/57 (2006.01); A61K 31/593 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/24 (2006.01); A61K 47/28 (2006.01); A61K 31/567 (2006.01); A61F 2/30 (2006.01); A61L 27/54 (2006.01); A61L 27/58 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0024 (2013.01); A61F 6/08 (2013.01); A61F 6/22 (2013.01); A61K 9/0002 (2013.01); A61K 31/167 (2013.01); A61K 31/192 (2013.01); A61K 31/325 (2013.01); A61K 31/567 (2013.01); A61K 31/57 (2013.01); A61K 31/593 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/24 (2013.01); A61K 47/28 (2013.01); A61F 2002/30677 (2013.01); A61L 27/54 (2013.01); A61L 27/58 (2013.01); A61L 2300/404 (2013.01);
Abstract

A drug delivery system is provided in the form of a controlled release, bioerodible pellet for subdermal implantation. The pellet is bioerodible, and provides for the sustained release of a pharmacologically active agent over an extended time period. As such, the drug delivery system finds significant utility in chronic drug administration. Bioerosion products are water soluble, bioresorbed, or both, obviating the need for surgical removal of the implant. Methods for manufacturing and using the drug delivery system are also provided.

Find Patent Forward Citations

Loading…